22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › Mirum Pharmaceuticals, Inc. › 2024-2025

Mirum Pharmaceuticals, Inc. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Mirum Pharmaceuticals, Inc.’s Form 8-K, filed May 30, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 248Asset managers, any item
  • 1,327Fund votes
  • May 29, 2025Meeting date

Results at a glance

Meeting of May 29, 2025: 5 items on Mirum Pharmaceuticals, Inc.’s Form 8-K, filed May 30, 2025: 2 approved · 2 passed (calculated) · 1 plurality election.

Dissent

Significant dissent: 1 director (50.3% against).

Notable dissent: 1 director (14.8% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Tang Capital (13F, 1.9%, as of September 30, 2026)

Explore Mirum Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Mirum Pharmaceuticals, Inc.

These tallies are Mirum Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 30, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Mirum Pharmaceuticals, Inc. — official shareholder meeting results, meeting held May 29, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Laura Brege 17,968,766---- 18,167,0977,017,835 49.7%Plurality election—
Elect Director: Michael Grey 30,777,470---- 5,358,3937,017,835 85%Passed (calculated)—
Elect Director: Christopher Peetz 35,980,278---- 155,5857,017,835 99.6%Passed (calculated)—
2. Ratification of the Selection of Independent Registered Public Accounting Firm 43,115,13419,18819,376 ---- 99.9%Approved—
3. Advisory Vote on Executive Compensation 34,671,8261,455,1438,894 --7,017,835 96%Approved—

Source: Mirum Pharmaceuticals, Inc., Form 8-K, filed with the SEC on May 30, 2025 — read the filing on EDGAR.

How asset managers voted at the Mirum Pharmaceuticals, Inc. 2024-2025 meeting

248 asset managers disclosed a vote on at least one Mirum Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Christopher Peetz

Calculated outcomeFund totals may overlapDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 35,980,278WITHHELD: 155,585
Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Christopher Peetz

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Christopher Peetz”): 35,980,278 for, 155,585 withheld, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 73 asset managers voting on “To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meet” at Mirum Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,516,3440 00For
Vanguard2,491,6370 00For
JANUS INVESTMENT FUND1,880,3460 00For
BlackRock1,084,4140 00For
T. Rowe Price982,1030 00For
Legg Mason794,7400 00For
Fidelity776,9760 00For
TIAA628,3490 00For
State Street521,1620 00For
Lord Abbett379,2820 00For
Loomis Sayles329,2040 00For
Charles Schwab327,6900 00For
Federated Hermes327,0100 00For
Invesco284,6000 00For
Waddell & Reed247,7790 00For
FRANKLIN STRATEGIC SERIES215,1900 00For
Columbia Threadneedle157,3310 00For
Equitable149,3930 00For
First Trust128,7740 00For
Brighthouse106,8340 00For
Russell Investments94,3130 00For
JPMorgan89,1720 00For
Calamos85,5930 00For
BNY Mellon82,4260 00For
QUANTITATIVE MASTER SERIES LLC67,6870 00For

Fund voting reports, all 73 managers: 15,396,904 for, 3,228 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meet” at Mirum Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH00 0260,000Withhold
BOSUN ASSET MANAGEMENT, LLC3,4900 00For
RWC Asset Management LLP2,8070 00For

Institutional-manager reports, all 3 managers: 6,297 for, 260,000 withheld.

Elect Director: Laura Brege

Calculated outcomeFund totals may overlapDIRECTOR ELECTIONSPlurality election

Combines 4 wordings of this item as funds reported it.

49.7% Plurality election · of votes cast

FOR 49.7%WITHHELD
FOR: 17,968,766WITHHELD: 18,167,097
Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Laura Brege

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Laura Brege”): 17,968,766 for, 18,167,097 withheld, per its Form 8-K filed May 30, 2025 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.

Outcome: Plurality election — The company’s filing reports the vote counts but does not state the outcome; this is an election decided by plurality, so a nominee does not need a majority of the votes cast and no passed or failed outcome is calculated.
Support: 49.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 73 asset managers voting on “To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meet” at Mirum Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,516,3440 00For
Vanguard2,459,9370 031,700For
JANUS INVESTMENT FUND00 01,880,346Withhold
BlackRock11,3750 01,073,039Withhold
T. Rowe Price982,1030 00For
Legg Mason792,1930 02,547For
Fidelity738,0350 038,941Mixed
TIAA628,3490 00For
State Street1,2740 0519,888Withhold
Lord Abbett00 0379,282Withhold
Loomis Sayles00 0329,204Withhold
Charles Schwab327,6900 00For
Federated Hermes327,0100 00For
Invesco00 0284,600Withhold
Waddell & Reed00 0247,779Withhold
FRANKLIN STRATEGIC SERIES00 0215,190Withhold
Columbia Threadneedle00 0157,331Withhold
Equitable00 0149,393Withhold
First Trust00 0128,774Withhold
Brighthouse33,1800 073,654Mixed
Russell Investments00 094,313Withhold
JPMorgan89,1720 00For
Calamos85,5930 00For
BNY Mellon82,4260 00For
QUANTITATIVE MASTER SERIES LLC00 067,687Withhold

Fund voting reports, all 73 managers: 9,217,505 for, 6,182,627 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meet” at Mirum Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH260,0000 00For
BOSUN ASSET MANAGEMENT, LLC3,4900 00For
RWC Asset Management LLP2,8070 00For

Institutional-manager reports, all 3 managers: 266,297 for.

Elect Director: Michael Grey

Calculated outcomeFund totals may overlapDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD
FOR: 30,777,470WITHHELD: 5,358,393
Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meeting of stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Michael Grey

Mirum Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Michael Grey”): 30,777,470 for, 5,358,393 withheld, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 73 asset managers voting on “To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meet” at Mirum Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,516,3440 00For
Vanguard2,491,6370 00For
JANUS INVESTMENT FUND1,880,3460 00For
BlackRock00 01,084,414Withhold
T. Rowe Price982,1030 00For
Legg Mason794,7400 00For
Fidelity760,7350 016,241For
TIAA628,3490 00For
State Street1,8620 0519,300Withhold
Lord Abbett379,2820 00For
Loomis Sayles329,2040 00For
Charles Schwab327,6900 00For
Federated Hermes327,0100 00For
Invesco284,6000 00For
Waddell & Reed00 0247,779Withhold
FRANKLIN STRATEGIC SERIES215,1900 00For
Columbia Threadneedle157,3310 00For
Equitable36,8830 0112,510Mixed
First Trust128,7740 00For
Brighthouse106,8340 00For
Russell Investments94,3130 00For
JPMorgan89,1720 00For
Calamos85,5930 00For
BNY Mellon82,4260 00For
QUANTITATIVE MASTER SERIES LLC00 067,687Withhold

Fund voting reports, all 73 managers: 13,170,405 for, 2,229,727 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “To elect the Board's three Class III nominees for director to hold office until the Company's 2028 annual meet” at Mirum Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH260,0000 00For
BOSUN ASSET MANAGEMENT, LLC3,4900 00For
RWC Asset Management LLP2,8070 00For

Institutional-manager reports, all 3 managers: 266,297 for.

Advisory Vote on Executive Compensation

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 34,671,826AGAINST: 1,455,143

Prior year: 96.7% for (June 5, 2024 meeting) ▼ 0.7 pts

Details: description as filed, official tally, votes by 248 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

Mirum Pharmaceuticals, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 34,671,826 for, 1,455,143 against — passed, per its Form 8-K filed May 30, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement for the Annual Meeting.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 74 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Mirum Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,516,3440 00For
Vanguard2,491,6370 00For
JANUS INVESTMENT FUND1,880,3460 00For
BlackRock1,084,4140 00For
T. Rowe Price982,1030 00For
Legg Mason794,7400 00For
Fidelity776,9760 00For
TIAA628,3490 00For
State Street521,1620 00For
Lord Abbett379,2820 00For
Loomis Sayles329,2040 00For
Charles Schwab327,6900 00For
Federated Hermes327,0100 00For
Invesco284,6000 00For
Waddell & Reed247,7790 00For
FRANKLIN STRATEGIC SERIES215,1900 00For
Columbia Threadneedle0157,331 00Against
Equitable149,3930 00For
First Trust128,7740 00For
Brighthouse106,8340 00For
Russell Investments94,3130 00For
JPMorgan89,1720 00For
Calamos85,5930 00For
BNY Mellon082,426 00Against
QUANTITATIVE MASTER SERIES LLC67,6870 00For

Fund voting reports, all 74 managers: 15,162,260 for, 254,500 against, 3,228 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 197 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Mirum Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Janus Henderson4,677,6590 00For
BVF INC/IL2,761,3330 00For
Novo Holdings A/S1,500,0000 00For
T. Rowe Price1,349,8690 00For
State Street1,301,0600 00For
Clearbridge Investments, LLC968,5460 00For
Rock Springs Capital Management LP951,7650 00For
BlackRock907,3790 00For
GEODE CAPITAL MANAGEMENT, LLC732,3350 00For
Citadel727,3810 00For
PICTET ASSET MANAGEMENT SA704,9540 00For
Nuveen654,7220 00For
BOONE CAPITAL MANAGEMENT LLC603,3180 00For
FRANKLIN ADVISERS INC592,5140 00For
LORD, ABBETT & CO. LLC588,5520 00For
Loomis Sayles555,3790 00For
Point72447,3610 00For
DE Shaw396,4150 00For
Candriam S.C.A.0369,198 00Against
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST357,8280 00For
AXA INVESTMENT MANAGERS UK Ltd0351,372 00Against
Federated Hermes336,0500 00For
Charles Schwab327,6960 00For
Invesco303,1870 00For
UniSuper Management Pty Ltd274,1410 00For

Institutional-manager reports, all 197 managers: 25,427,233 for, 1,115,502 against, 7,822 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Selection of Independent Registered Public Accounting Firm

Official resultFund totals may overlapAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 43,115,134AGAINST: 19,188

Prior year: 99.9% for (June 5, 2024 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 75 asset managers

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.

Mirum Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 43,115,134 for, 19,188 against — passed, per its Form 8-K filed May 30, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending …”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Mirum Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, 21,025 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 72 asset managers voting on “To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independe” at Mirum Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST2,516,3440 00For
Vanguard2,491,6370 00For
JANUS INVESTMENT FUND1,880,3460 00For
BlackRock1,084,4140 00For
T. Rowe Price982,1030 00For
Legg Mason794,7400 00For
Fidelity776,9760 00For
TIAA628,3490 00For
State Street521,1620 00For
Lord Abbett379,2820 00For
Loomis Sayles329,2040 00For
Charles Schwab327,6900 00For
Federated Hermes327,0100 00For
Invesco284,6000 00For
Waddell & Reed247,7790 00For
FRANKLIN STRATEGIC SERIES215,1900 00For
Columbia Threadneedle157,3310 00For
Equitable149,3930 00For
First Trust128,7740 00For
Brighthouse106,8340 00For
Russell Investments94,3130 00For
JPMorgan89,1720 00For
Calamos85,5930 00For
BNY Mellon82,4260 00For
QUANTITATIVE MASTER SERIES LLC67,6870 00For

Fund voting reports, all 72 managers: 15,395,735 for, 3,228 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independe” at Mirum Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH260,0000 00For
BOSUN ASSET MANAGEMENT, LLC3,4900 00For
RWC Asset Management LLP2,8070 00For

Institutional-manager reports, all 3 managers: 266,297 for.

Largest Mirum Pharmaceuticals, Inc. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 49,451,223 shares outstanding at the time of that meeting.

Fund voting reports: top Mirum Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1MUTUAL FUND SERIES TRUST 5.09%
2Vanguard 5.04%
3JANUS INVESTMENT FUND 3.80%
4BlackRock 2.19%
5T. Rowe Price 1.99%
6Legg Mason 1.61%
7Fidelity 1.57%
8TIAA 1.27%
9State Street 1.05%
10Lord Abbett 0.77%
Institutional-manager reports: top Mirum Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1Janus Henderson 9.46%
2BVF INC/IL 5.58%
3Novo Holdings A/S 3.03%
4T. Rowe Price 2.73%
5State Street 2.63%
6Clearbridge Investments, LLC 1.96%
7Rock Springs Capital Management LP 1.92%
8BlackRock 1.83%
9GEODE CAPITAL MANAGEMENT, LLC 1.48%
10Citadel 1.47%

Reported Mirum Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Mirum Pharmaceuticals, Inc. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
JANUS HENDERSON GROUP PLC6,065,308 12.27%Schedule 13G, filed February 17, 2026
James N. Topper4,025,922 8.14%Schedule 13D, filed January 27, 2026
Patrick Heron3,797,220 7.68%Proxy statement (DEF 14A), table as of February 15, 2025
Frazier Life Sciences IX, L.P.3,566,912 7.21%Schedule 13D, filed November 4, 2025
BlackRock3,339,557 6.75%Form 13F, quarter ended March 31, 2025
Biotechnology Value Fund, L.P.3,075,907 6.22%Proxy statement (DEF 14A), table as of February 15, 2025
Vanguard Group2,540,061 5.14%Form 13F, quarter ended March 31, 2025
Eventide Asset Management, LLC2,093,582 4.23%Schedule 13G, filed February 13, 2026
Christopher Peetz1,717,976 3.47%Proxy statement (DEF 14A), table as of February 15, 2025
BVF PARTNERS L P/IL1,495,290 3.02%Schedule 13G, filed November 14, 2025

Percentages above are of 49,451,223 shares outstanding, as reported by Mirum Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Mirum Pharmaceuticals, Inc.'s shareholder meeting held May 29, 2025, in the 2024-2025 proxy season, 248 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,327 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — Mirum Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Mirum Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 30, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Mirum Pharmaceuticals, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Mirum Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “Mirum Pharmaceuticals (MIRM) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/mirum-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.